NASDAQ:BMEA
Biomea Fusion, Inc. Stock Company Profile
$12.35
+0.420 (+3.52%)
At Close: May 03, 2024
Information
900 Middlefield Road, 4th Floor
Redwood City CA 94063
650 980 9099
biomeafusion.com
Industry: Biotechnology
Sector: Healthcare
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.